IL6 and hyperlipidemia: The hyperglycemic state and hyperlipidemia in turn activate glycation end products (AGEs), whose receptors are on monocytes, endothelial cells and macrophages, which secrete interleukin 1β (IL-1β), interleukin 6 (IL-6), Prostaglandin E2 (PGE2) and tumor necrosis factor alpha (TNF-α) [14,15].